Aspire Advances its Growth Trajectory with Acquisition of Cenoté Pharma Ltd.
Petersfield, Hampshire, 11 March 2024, Aspire Pharma Limited, a rapidly growing specialty generics business, continues to supplement its strong organic growth with acquisitions and strategic partnerships with the successful completion of its acquisition of Cenoté Pharma Ltd.
Cenoté Pharma is a category specialist in carnitine deficiencies. Carnitine is an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscle. The exact prevalence of systemic primary carnitine deficiency (SPCD) is unknown and varies depending on ethnicity. The estimated prevalence is 1 in 20,000 to 1 in 70,000 newborns in Europe and the USA. 1
“We are excited to bring an additional therapy area into our portfolio at Aspire. This acquisition underscores our commitment to advance the science and treatment options for vulnerable patient groups, with Aspire’s capabilities, we will also push to gain regulatory approval in multiple global markets in the near future.”
~ Richard Condon, Chief Executive Officer of Aspire.
The acquisition of Cenoté represents the fourth acquisition Aspire has completed since being acquired by an affiliate of H.I.G. Capital in 2021, and further strengthens its specialty pharma offering. In addition, Aspire has completed over 20 licensing agreements in the last 12 months alone.
As the Company continues to expand its presence in continental Europe, it is actively seeking bolt-on acquisitions across Germany, Spain and the Nordic region as well as partnerships with pharma companies on both in- and out-licensing opportunities.
- Orphanet. Systemic primary carnitine deficiency. Available at: https://www.orpha.net. (Last accessed 16 February, 2024)
